文献速递白血病

CSF1R抑制剂通过阻断支持细胞的旁分泌信号在急性髓系白血病中显示抗肿瘤活性

CSF1R inhibitors exhibit antitumor activity in acute myeloid leukemia by blocking paracrine signals from support cells.
PubMed 文献 · Blood · 2018-11-13

研究对原发急性髓系白血病(AML)患者样本进行小分子和siRNA筛选,发现23%的样本对CSF1R抑制剂敏感。CSF1R主要表达于支持细胞亚群而非白血病母细胞,其数量与药物敏感性相关。CSF1R抑制剂GW-2580可减少AML样本条件培养基中HGF等细胞因子分泌,而重组HGF或HS-5条件培养基可挽救GW-2580处理后的细胞活力。结果表明CSF1R表达细胞通过分泌HGF等细胞因子支持白血病群体,CSF1R是AML的潜在治疗靶点。

要点

  • 23%的原发AML患者样本对CSF1R抑制剂敏感,敏感性与新发及有利风险相关。
  • CSF1R表达于支持细胞亚群而非大多数白血病母细胞,其数量与GW-2580敏感性相关。
  • CSF1R抑制剂减少HGF等细胞因子分泌,重组HGF或HS-5条件培养基可挽救细胞活力。

核心结论

  • CSF1R表达细胞通过分泌HGF等细胞因子支持白血病群体,CSF1R是AML的新治疗靶点。

研究设计与样本

  • 对原发AML患者样本进行小分子和siRNA筛选,并用流式细胞术和质谱流式分析CSF1R表达细胞。

主要发现

  • 23%的样本对CSF1R抑制敏感,敏感者多见于新发和有利风险患者,耐药与总生存降低相关。
  • CSF1R主要表达于支持细胞亚群,其数量与GW-2580敏感性相关。
  • CSF1R抑制剂敏感性 correlates with growth response to CSF1 and HGF等细胞因子。

关键数值与推荐

  • 原文未报告具体阈值、剂量或统计值。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

To identify new therapeutic targets in acute myeloid leukemia (AML), we performed small-molecule and small-interfering RNA (siRNA) screens of primary AML patient samples. In 23% of samples, we found sensitivity to inhibition of colony-stimulating factor 1 (CSF1) receptor (CSF1R), a receptor tyrosine kinase responsible for survival, proliferation, and differentiation of myeloid-lineage cells. Sensitivity to CSF1R inhibitor GW-2580 was found preferentially in de novo and favorable-risk patients, and resistance to GW-2580 was associated with reduced overall survival. Using flow cytometry, we discovered that CSF1R is not expressed on the majority of leukemic blasts but instead on a subpopulation of supportive cells. Comparison of CSF1R-expressing cells in AML vs healthy donors by mass cytometry revealed expression of unique cell-surface markers. The quantity of CSF1R-expressing cells correlated with GW-2580 sensitivity. Exposure of primary AML patient samples to a panel of recombinant cytokines revealed that CSF1R inhibitor sensitivity correlated with a growth response to CSF1R ligand, CSF1, and other cytokines, including hepatocyte growth factor (HGF). The addition of CSF1 increased the secretion of HGF and other cytokines in conditioned media from AML patient samples, whereas adding GW-2580 reduced their secretion. In untreated cells, HGF levels correlated significantly with GW-2580 sensitivity. Finally, recombinant HGF and HS-5-conditioned media rescued cell viability after GW-2580 treatment in AML patient samples. Our results suggest that CSF1R-expressing cells support the bulk leukemia population through the secretion of HGF and other cytokines. This study identifies CSF1R as a novel therapeutic target of AML and provides a mechanism of paracrine cytokine/growth factor signaling in this disease.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Edwards DK, Watanabe-Smith K, Rofelty A, et al. CSF1R inhibitors exhibit antitumor activity in acute myeloid leukemia by blocking paracrine signals from support cells. Blood. 2018. PMID: 30425048. doi:10.1182/blood-2018-03-838946

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。